Clinical Trial to Study the Safety and Tolerability of Memantin Mepha® in Sickle Cell Disease Patients
Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
Symptomatic sickle cell disease is worldwide the most frequent cause for hereditary hemolytic
anemia with recurrent pain crisis. Hemolysis, vaso- occlusive and pain crises are hallmarks
of this disease and are causative for an important socio-economic burden worldwide,
especially in Africa.
Aside from allogenic stem cell transplantation, which is rarely available and very expensive,
at present there is no curative treatment for patients with sickle cell disease (SCD). The
current standard of care includes treatment with hydroxycarbamide and symptomatic care such
as transfusions, antibiotic/analgesic treatment.
This study has the aim to study the safety and tolerability of Memantin in patients with
sickle cell disease.